drugset

drugset / Trial / NCT00150423

To Evaluate the Safety and Efficacy of Pregabalin in Patients With Painful Diabetic Peripheral Neuropathy.

NCT00150423 ↗

Phase 3 Completed 384 enrolled Pfizer

Non-randomizedSingle-groupOpen-labelTreatment

Summary

To evaluate the safety and efficacy of pregabalin in patients with painful diabetic peripheral neuropathy.

Timeline

Start: 2001-01
Primary completion: —
Completion: 2005-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pregabalin	Small molecule	—	—

Indications